ESLA

Estrella Immunopharma, Inc. (ESLA) | Rumor.io

Estrella Immunopharma

ESLA

Attention (50-day avg)0%

Attention rank (50-day avg)#4,611

Bullish sentiment (50-day avg)0%

Price to earnings ratio-1.23

Market capitalization18.7M

Earnings per share-0.22

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-13.1M

Social

What share of all stock conversation is about ESLA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Feb 6

Estrella Immunopharma's stock fell by 22.8% amid pre-presentation jitters.
The company's stock surged by 21.2% after announcing a late-breaking oral presentation of Phase 1 data.
Estrella Immunopharma's stock fell by 22.9% following the late-breaking presentation of Phase 1 data, but some analysts remain optimistic about the company's prospects.

Generated by AI

Sentiment

Of the messages about ESLA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	85.92% +11.89
Bearish	—	—	—	14.08% -11.89

Feb 5

$ESLA has shown strong relative performance compared to the market, maintaining gains while others experienced losses, which is a bullish signal.
$ESLA is demonstrating strong relative strength versus the market, holding gains while others chop, indicating a bullish sign.
$ESLA is building momentum, with buyers in control, and could see more upside ahead.

Generated by AI

Topics

Of the messages about ESLA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	52.53%
Analysts	—	—	0%	1.01%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	7.07%
Technical Analysis	—	—	0%	39.39%

Community

Of the messages about ESLA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	21.58%
Newcomers	—	—	0%	78.42%

Feb 5

The newcomer is focused on the potential of Estrella Immunopharma's ARTEMIS T-cell therapies, specifically highlighting the company's approach to targeting CD19/CD22 for cancer and autoimmune disease treatment.
The newcomer is paying close attention to the company's recent Phase 1 data presentation, noting the late-breaking oral presentation of the STARLIGHT-1 data for EB103 at the 2026 Tandem.
The newcomer believes the company's stock has significant upside potential, with buyers currently in control of the market, suggesting a positive outlook for Estrella Immunopharma's shares.

Generated by AI

By David Bautz, PhD NASDAQ: ESLA READ THE FULL ESLA RESEARCH REPORT Business Update STARLIGHT I Dose Expansion Underway Estrella Immunopharma (NASDAQ: ESLA) is currently conducting the Phase 1/2 STARLIGHT-1 trial of EB103 in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL). The company recently announced that the first patient was dosed in the expansion phase, following

1mo agoYahoo Finance

Estrella adds fourth site to EB103 lymphoma trial

1mo agoInvesting.com

Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

EMERYVILLE, Calif., August 11, 2026--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a fourth clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory (R/R) B-cell non-Hodgkin’s lympho

1mo agoYahoo Finance

Estrella adds third site to EB103 lymphoma trial

1mo agoInvesting.com

Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

EMERYVILLE, Calif., August 03, 2026--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a third clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory ("R/R") B-cell non-Hodgkin’s lymph

1mo agoYahoo Finance

Estrella activates second site for EB103 lymphoma trial

2mo agoInvesting.com

Also Discussed

Investors talking about ESLA also mention

#	Name	Attention
1	MSPR - MSP Recovery, Inc.	——
2	DTCK - Davis Commodities Limited Ordinary Shares	——
3	UPTD - TradeUP Acquisition Corp.	——
4	Heritage Global Inc.HGBL	0%0
5	Sight Sciences, Inc.SGHT	0%new
6	Stoke Therapeutics, Inc.STOK	0%new
7	Fulcrum Therapeutics, Inc.FULC	0%0
8	Creative Media & Community Trust CorporationCMCT	0%0
9	Rallybio Corp.RLYB	0%0
10	Celcuity Inc.CELC	0%0

Estrella Immunopharma, Inc.

Healthcare
Biotechnology

Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing T-cell therapies for blood cancers, solid tumors, and certain autoimmune diseases. The company is centered on CD19- and CD22-targeted ARTEMIS T-cell programs designed to harness the immune system’s ability to recognize and attack diseased cells. Its current pipeline includes EB103 and EB104 for B-cell malignancies, along with EB201, which is being explored for systemic lupus erythematosus. Estrella Immunopharma operates in the advanced immunotherapy and cell therapy segment of the biopharmaceutical market, where it aims to address treatment challenges through engineered immune-based approaches. Headquartered in Emeryville, California, Estrella Immunopharma is positioned as a research-driven company developing next-generation therapies for oncology and autoimmune disorders.

Website

Location

5858 Horton Street

EmeryVille, CA, 94608

United States

Social

What share of all stock conversation is about ESLA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Feb 6

Estrella Immunopharma's stock fell by 22.8% amid pre-presentation jitters.
The company's stock surged by 21.2% after announcing a late-breaking oral presentation of Phase 1 data.
Estrella Immunopharma's stock fell by 22.9% following the late-breaking presentation of Phase 1 data, but some analysts remain optimistic about the company's prospects.

Generated by AI

Sentiment

Of the messages about ESLA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	85.92% +11.89
Bearish	—	—	—	14.08% -11.89

Feb 5

$ESLA has shown strong relative performance compared to the market, maintaining gains while others experienced losses, which is a bullish signal.
$ESLA is demonstrating strong relative strength versus the market, holding gains while others chop, indicating a bullish sign.
$ESLA is building momentum, with buyers in control, and could see more upside ahead.

Generated by AI

Topics

Of the messages about ESLA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	52.53%
Analysts	—	—	0%	1.01%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	7.07%
Technical Analysis	—	—	0%	39.39%

Community

Of the messages about ESLA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	21.58%
Newcomers	—	—	0%	78.42%

Feb 5

The newcomer is focused on the potential of Estrella Immunopharma's ARTEMIS T-cell therapies, specifically highlighting the company's approach to targeting CD19/CD22 for cancer and autoimmune disease treatment.
The newcomer is paying close attention to the company's recent Phase 1 data presentation, noting the late-breaking oral presentation of the STARLIGHT-1 data for EB103 at the 2026 Tandem.
The newcomer believes the company's stock has significant upside potential, with buyers currently in control of the market, suggesting a positive outlook for Estrella Immunopharma's shares.

Generated by AI

Estrella Immunopharma

Social

Feb 6

Sentiment

Feb 5

Topics

Community

Feb 5

News

ESLA: First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial

Estrella adds fourth site to EB103 lymphoma trial

Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

Estrella adds third site to EB103 lymphoma trial

Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

Estrella activates second site for EB103 lymphoma trial

Also Discussed

Estrella Immunopharma, Inc.

Company Information

Location

News

ESLA: First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial

Estrella adds fourth site to EB103 lymphoma trial

Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

Estrella adds third site to EB103 lymphoma trial

Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

Estrella activates second site for EB103 lymphoma trial

Also Discussed

Social

Feb 6

Sentiment

Feb 5

Topics

Community

Feb 5